Biotech stocks are rallying strongly in 2026, with the iShares Biotechnology ETF up 24% year-to-date, building on a 28% gain in 2025. Moderna leads with a 587% surge despite a recent dip after positive cancer vaccine data leaked. The sector's growth is driven by breakthroughs in mRNA, genomics, AI-driven drug discovery, and robust clinical trial results, including promising cancer and obesity treatments. Increased M&A activity and a strong pipeline of novel drugs also support optimism for continued gains and innovation in biotech through 2027 and beyond.
Moderna's market cap stands at $79.89 billion as of Oct 25, 2026, 02:11 WIB, with a daily trading volume of over 21 million shares on Pluang. Despite a recent 1.25% dip in price to $200.10, the stock sees a high sell activity of 79% among Pluang users, reflecting active repositioning amid the biotech surge. The typical hold time for Moderna shares on Pluang is 58 days, indicating moderate-term investor engagement in this fast-evolving sector.
Moderna and Merck released Phase 3 trial results showing their personalized mRNA cancer vaccine, combined with Keytruda, reduces melanoma recurrence or death risk by 42% compared to Keytruda alone. Specialists see this as a significant breakthrough t...
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firm...
Moderna's stock dropped sharply by over 21% in two days following the leak of early Phase 3 trial results for its personalized cancer vaccine and a major downgrade from Citi, which issued a 'Sell' rating and an $80 price target. Despite the leaked re...
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
